您当前所在的位置:首页 > 产品中心 > 产品信息
Levorphanol_分子结构_CAS_77-07-6)
点击图片或这里关闭

Levorphanol

产品号 DB00854 公司名称 DrugBank
CAS号 77-07-6 公司网站 http://www.ualberta.ca/
分子式 C17H23NO 电 话 (780) 492-3111
分子量 257.37062 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 732

产品价格信息

请登录

产品别名

标题
Levorphanol
IUPAC标准名
(1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-trien-4-ol
IUPAC传统名
levorphanol
商标名
Antalgin
Aromarone
Cetarin
Dromoran
Racemic Dromoran
Lemoran
Levo-Dromoran
别名
Levorphanol Dl-Form
Dea No. 9220
Levorfanolo [Dcit]
Levorphanolum [INN-Latin]
Dea No. 9733
Methorfinan [Czech]
Racemethorphanum
Racemorfano [INN-Spanish]
Levorphanal
Levorphan
Levorfanol [INN-Spanish]
Levorphanol Tartrate
Methorphinan

产品登记号

CAS号 77-07-6

产品性质

疏水性(logP) 3.3
溶解度 1840 mg/L

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection. [PubChem]
Indication For the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate
Pharmacology Levorphanol is a potent synthetic opioid analgesic indicated for the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate. Levorphanol is similar to morphine in its actions, however it is up to 8 times more potent than morphine. Levorphanol produces a degree of respiratory depression similar to that produced by morphine at equianalgesic doses, and like many mu-opioid drugs, levorphanol produces euphoria or has a positive effect on mood in many individuals.
Toxicity LD50=150 mg/kg (orally in rats). Signs of overdose include nausea, emesis, dizziness, respiratory depression, hypotension, urinary retention, cardiac arrhythmias, allergic reactions, skin rash, and uticaria.
Affected Organisms
Humans and other mammals
Biotransformation Levorphanol is extensively metabolized in the liver and is eliminated as the glucuronide metabolite.
Absorption Levorphanol is well absorbed after PO administration with peak plasma concentrations occurring approximately 1 hour after dosing.
Half Life 11-16 hours
Protein Binding 40%
Distribution * 10 to 13 L/kg
Clearance * 0.78 to 1.1 L/kg/hr
External Links
Wikipedia
RxList
Drugs.com

参考文献